FOR ADULTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA
LIVE PROGRESSION FREE
In 2 different trials, patients lived progression free longer when
treated with sarclisa plus other therapies.
Trial 1: At a median follow-up of 44 months, patients lived progression free for a median of 41.7 months with SARCLISA + Kyprolis (carfilzomib) and dexamethasone (Kd) vs 20.8 months with Kd alone. At the time of this analysis, 56% (101 of 179 patients) lived progression free with SARCLISA + Kd vs 45% (55 of 123 patients) treated with Kd alone. In an earlier analysis, at a median follow-up of 20.7 months, 74% (133 of 179 patients) lived progression free with SARCLISA + Kd vs 59% (73 of 123 patients) treated with Kd alone.
Trial 2: At a median follow-up of 11.6 months, patients lived progression free for a median of 11.53 months with SARCLISA + Pomalyst® (pomalidomide) and dexamethasone (Pd) vs 6.47 months with Pd alone. At the time of this analysis, 53% (81 of 154 patients) lived progression free with SARCLISA + Pd vs 42% (64 of 153 patients) treated with Pd alone.
A median is the middle number in a group of numbers ordered from smallest to largest.
Find out more about the ~42 months results from the Phase 3 trial.
Sanofi CareASSIST may be able to help address your financial assistance concerns
We understand that you may have concerns about paying for your treatment. If
you experience a change or loss in coverage, Sanofi CareASSIST may be able to help.
You can call 1-833-WE+CARE(1-833-930-2273), and a Patient Access
Specialist will review your specific eligibility during this time. Please click here.
To learn about the Sanofi response to COVID-19, please click here.
NOW FDA APPROVED A NEW TREATMENT OPTION
Read the official press release and talk
with your doctor to learn more.
This information is intended for US Healthcare Professionals only.
Select the “Continue” button below to go to the page you requested, or the “Cancel”
button to return to
the previous page.
You are about to leave SARCLISA.com.
Sanofi does not review or control the content of non–Sanofi
websites, and this hyperlink
does not constitute an endorsement by Sanofi of the site's
content. Sanofi's privacy
procedures do not apply to the owners of a non–Sanofi website.
You are about to leave sanofi site for U.S.
Sanofi US does not review the information
contained on this website and/or database
for content, accuracy or completeness. Use
of and access to this information is subject to
the terms, limitations and conditions set by the
website and/or database producer.
This site might not comply with the regulatory requirements of US